EGFR/ERBB1 Research Reagents: From Signaling Studies to Targeted Therapy Development

EGFR (epidermal growth factor receptor, ERBB1) is a receptor tyrosine kinase that drives cell proliferation, survival, and migration across multiple solid tumor types. For a broader view of all oncology reagent categories, see our Cancer Research Reagents hub.

Target Biology and Clinical Relevance

EGFR is overexpressed or mutated in NSCLC (activating mutations: exon 19 del, L858R), CRC (wild-type EGFR amplification), HNSCC, and GBM (EGFRvIII variant). EGFR belongs to the same ERBB receptor family as HER2/ERBB2. EGFR-targeted therapies include monoclonal antibodies (cetuximab, panitumumab) and TKIs (erlotinib, gefitinib, osimertinib, amivantamab).

Anti-EGFR antibodies are validated for IHC (tumor expression scoring), WB (total EGFR and phospho-EGFR Y1068/Y1173), flow cytometry, and IP. Phospho-specific antibodies enable monitoring of pathway activation status.

Recombinant EGFR ECD proteins serve as ligands for SPR/BLI, coating antigens for ELISA, and immunogens. Research biosimilar cetuximab and panitumumab are available for competitive binding, ADCC assays, and PK/ADA bioanalytical method development. EGFR is also an important target in emerging ADC programs (e.g., amivantamab).

EGFRvIII (deletion of exons 2–7) is a constitutively active variant found in ~30% of GBM. EGFRvIII-specific antibodies and proteins are available for research on this tumor-specific neoantigen.

abinScience Product Coverage

References

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. doi: 10.1038/35052073

2. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3

3. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

All products are for research use only. For technical support, contact order@abinscience.com.